Redeye interviewed Øystein Rekdal about Lytix and his role as CEO

The positive interim Phase II data with LTX-315 from Verrica Pharmaceuticals Inc. (Lytix Biopharma’s licensing partner) stirs attention

Redeye initiates coverage of Lytix Biopharma

Lytix Biopharma’s innovative and unique solution emphasized in national clinical research report

Hear our CEO, Øystein Rekdal, explaining how our technology has the potential to solve the major challenge in current cancer therapy